Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 629-636

  Teus, Miguel A ^a   Miglior, Stefano ^b   Laganovska, Guna ^c   Volksone, Lasma ^d   Romanowska Dixon, Bozena ^e   Gos, Roman ^f   Holló, Gábor ^g  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^d Clinical Hospital Gailezera   (Latvia)

^e UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^f Sp Z Oo ^*  (Poland)

^g SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Dorzolamide; Fixed combination; Glaucoma; IOP lowering therapy; Timolol; Travoprost

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL PLUS TRAVOPROST;

ABNORMAL SENSATION; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY SENSATION; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL;

EID: 77949891677     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s8011     Document Type: Article

References (16)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713; discussion 829-830.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
3. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15(2):132-135.
4. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242-250.
5. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.
6. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1-7.
7. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945-1951.
8. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134-142.
9. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106(5):997-1004; discussion 1004-1005.
10. Suzuki ER Jr, Franklin LM, da Silva LJ, Figueiredo CR, Netto JA, Batista WD. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22(9):1799-1805.
11. Chiseli D, Antohi I, Medvichi R, Danielescu C. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia. 2005;49(3):39-45.
12. Lafuma A, Berdeaux G. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database. Curr Med Res Opin. 2007;23(12):3009-3016.
13. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965-1972.
14. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110(4):495-499.
15. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217-222.
16. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26(3):233-236.